⚡ ABVX $2.1M ATM Call Bet — Dec $100 Strike Owns the NDA Filing Window

📅 June 12, 2026 | 🔥 Unusual Activity Detected

✅ Updated 2026-06-15: Next-day OPRA OI confirms the open — open interest rose 386 → 1,317 (Δ +931, larger than the 765 traded). The Dec $100 call bull position is confirmed on the books.

---

🎯 The Quick Take

At 10:03:38 this morning, someone paid ≈$2.1M to buy 765 Abivax (ABVX) December $100 calls — right at the money, with the stock sitting at ≈$99.78. These calls expire December 18, 2026, and that date matters: it's the exact window Abivax has guided for its U.S. NDA filing for obefazimod in ulcerative colitis — the single biggest regulatory event for this company's entire existence. Whoever bought these is making a patient, high-conviction bet that the NDA gets filed, or that Eli Lilly's reported ≈€15B takeover talks turn into an actual deal — all before year-end. The tradeoff? They paid a stunning $28 per contract on a $100 stock, which tells you everything you need to know about how wild this name is right now.

---

📊 Company Overview

Abivax SA (ABVX) is a French clinical-stage biotech trading as an ADR on NASDAQ:

• Market Cap: ≈$3–4B (mid-cap biotech ADR)
• Sector / Industry: Healthcare — Biotechnology (clinical-stage)
• What they do: Abivax is essentially a one-drug company. Their entire pipeline is built around obefazimod (ABX464) — a first-in-class oral pill that works by enhancing a small RNA called miR-124 to reduce gut inflammation. The target disease is ulcerative colitis (UC), a chronic inflammatory bowel disease affecting millions of patients who aren't well-controlled on existing biologics or JAK inhibitors. If approved, obefazimod would compete directly with AbbVie's Rinvoq, J&J's Stelara, and BMS's Zeposia in an IBD market projected to grow from ≈€20B today to ≈€41B by 2032.
• The June 2026 whipsaw, in one paragraph: Phase 3 maintenance data (ABTECT) posted ≈50–51% Week-44 remission versus ≈10% for placebo — genuinely best-in-class numbers. Yet the stock crashed ≈43% in a single day when a handful of malignancy cases surfaced at the higher 50 mg dose. It has since bounced from $72.50 back to ≈$100, sitting almost exactly at the $100 strike where today's call buyer stepped in.
• Cash runway: ≈€491.6M on hand as of March 31, 2026, funded into Q4 2027 — no imminent forced raise ahead of the NDA.

---

💰 The Option Flow Breakdown

The Tape — June 12, 2026 @ 10:03:38: ⚡ Lit call buy

Flow type: ⚡ Lit — Auto-execution. This was an electronic execution on the displayed lit book, not a negotiated block or a cross. The buyer consumed real displayed liquidity, paying ≈$28 per contract to open this position. Order type: BTO — Buy to Open.

---

✅ RESOLVED — Next-Day OI Confirms the Open (2026-06-15)

Open interest ROSE by 931 — more than the 765 contracts traded — so the Dec-2026 $100 call opened as a fresh bullish long position (with some additional buying alongside it). The earlier size-vs-OI read (765 size vs 386 prior OI) is confirmed: this is a new bull position heading into year-end, BTO-confirmed.

---

🤓 What This Actually Means — Plain English

Let's break this down clearly.

The option is absurdly expensive. That's not a mistake — it's the point.

Paying $28 for a call on a $100 stock means you're paying 28% of the stock's entire value just for the right to buy it. At expiration, the stock needs to be above $128 ($100 strike + $28 premium paid) for this trade to profit. That breakeven is ≈28% above today's spot price.

So why would someone pay that? Because this is not a normal stock. ABVX has a 52-week range of $5.69 to $148.83 — a name that has moved more than 25x from its lows. It dropped 43% in a single trading session just two weeks ago. Options on a stock like this are expensive because the market genuinely has no idea what's coming next. That uncertainty is priced as high implied volatility, which makes options cost a lot.

Translation for regular traders: on a stock that might double or get cut in half within six months, paying $28 for a call isn't greedy — it's the price of admission.

What does this call own? The buyer has the right to purchase ABVX at $100/share up through December 18, 2026. That 189-day window captures every key catalyst on the calendar:

• The U.S. NDA filing (guided late Q4 2026) — the single biggest near-term de-risking event.
• The full ABTECT safety dataset — which either clears the malignancy cloud or worsens it.
• Any Eli Lilly takeover news — a ≈€15B bid, if it happens, would send the stock dramatically higher.

The call buyer is not saying "I think ABVX will drift to $105." They're saying "I think something big happens before December 18 — NDA filing, deal, or safety clearance — and I want leveraged exposure with defined maximum loss."

The order type is BTO — Buy to Open. This is a new bullish position, proven by size (765 contracts vs 386 prior OI). The buyer paid ≈$2.1M and can lose 100% of that if ABVX closes below $100 on December 18. Their upside is uncapped if the stock re-rates toward the analyst consensus of ≈$136–$149.

---

📈 Technical Setup / Chart Check-Up

YTD Performance

The YTD chart tells the entire ABVX story in one image. The stock ran enormously from its 52-week low of $5.69 on the back of compelling early clinical data, ripping all the way to the $130s by late May 2026. Then came the ≈43% single-day collapse on June 2 when the malignancy signal hit the tape — a gut-punch from $132+ down to $72.50 in the span of hours.

What's notable is the recovery since: shares bounced sharply to $90.15 by June 3 and $104.93 by June 4, and now trade at ≈$99.78 — almost exactly back to the round $100 level where the call buyer entered today. The market is saying: the efficacy data was real, the safety concern is real, and the outcome is genuinely unknown.

Key observations:

• 📉 The June 2 crash erased ≈$2B in market cap in a single session
• 📈 The subsequent bounce suggests the market is treating the malignancy signal as a label risk, not a kill shot — consistent with how AbbVie's Rinvoq (a $8.3B/yr drug) carries a similar malignancy warning
• 🎯 Today's ≈$99.78 spot puts ABVX right at the $100 gamma wall — a technically loaded level

Gamma-Based Support & Resistance

Current Price: ≈$97.93 (gamma model) / ≈$99.78 (live spot)

ABVX is a thinly-optioned ADR, which means the gamma exposure chart is less mechanically dominant than it would be for a heavily-traded large-cap. The levels below are real, but market maker hedging flows are more modest than in a name like NVDA or SPY. With that caveat clearly stated, here's what the gex.json shows:

The dominant feature in the entire gamma landscape: $100 strike.

At $100, the chain holds by far the largest total gamma exposure of any strike — 2.81 (vs 1.14 at $90 and 1.09 at $95, the next closest). Call gamma and put gamma are almost equal at $100 (1.475 call vs 1.333 put), making this a near-perfect two-sided gravity point. In plain terms: options market makers have significant hedging exposure at $100, which should make that level act like a magnet. ABVX is likely to pin around $100 absent a major catalyst. That's exactly where the stock trades today.

🔵 Support Levels (Put Gamma Below Price):

• $95 — Moderate Support. Net put gamma creates a modest buffer. On a normal down day, $95 is the first level where selling pressure may slow.
• $90 — Stronger Support Floor. Both call and put gamma are elevated at $90 (combined 1.14), making it a more significant anchor. If the $100 pin breaks down, $90 is the next zone where the market tends to stabilize.
• $80 — Deep Support. If a negative catalyst sends the stock toward the June lows, $80 is where meaningful total gamma (0.54) comes back into play.

🟠 Resistance Levels (Call Gamma Above Price):

• $100 — The Pin / Gravity Point. With the stock AT $100 and gamma balanced here, this level is both support and resistance simultaneously. A sustained break above $100 on news would remove the gravitational pull and open the door to faster moves higher.
• $105 — Next Resistance Shelf. Call and put gamma both present at $105 (0.73 total) — a reasonable first target if $100 breaks clean.
• $110 — Material Resistance. 0.88 total gamma here; a level the bull case needs to clear en route to pre-crash highs.
• $125 / $130 — Where Call Gamma Reasserts. Open interest from the pre-crash era shows meaningful positioning in the $125–$135 zone; analyst price targets cluster in this range.

Translation for traders: ABVX is pinned at $100 by gamma. The Dec $100 call buyer is positioned right at the fulcrum — the trade works if a catalyst breaks the stock out of this gravitational zone to the upside.

Implied Move Analysis

The options market is pricing in extraordinary uncertainty for ABVX at every time horizon:

• 📅 Weekly (exp 2026-06-18, 6 days): ±$11.38 (±11.65%) → Range $86.33 – $109.09
• 📅 Monthly OPEX (exp 2026-07-17, 35 days): ±$34.62 (±35.44%) → Range $63.09 – $132.33
• 📅 Quarterly / Dec expiry (exp 2026-12-18, 189 days): ±$62.97 (±64.44%) → Range $34.74 – $160.68
• 📅 LEAP (exp 2027-03-19, 280 days): ±$72.73 (±74.44%) → Range $24.98 – $170.44

Let those numbers sink in. The December expiry cone — the exact option that was just bought — spans from $34.74 to $160.68. That is not a typo. The options market is literally saying that within the life of the Dec $100 call, Abivax could trade anywhere from $35 to $161. That's the price of owning a single-asset, binary-outcome biotech.

The breakeven of $128 sits comfortably inside the upper half of the December cone — and within the ≈$136–$149 analyst consensus range. The bull case is not unreasonable by any metric. But neither is the bear case.

Key takeaway: the monthly cone already reaches $132.33 by July 17 — above the breakeven. If the full safety dataset (expected 2H 2026) comes out clean, and/or an NDA filing announcement lands before December, the math toward the upper cone is very much in play.

---

🎪 Catalysts

Already Happened — What Got Us Here

Phase 3 ABTECT Induction (Earlier 2026) — Best-in-Class Signals Both ABTECT-1 and ABTECT-2 8-week induction trials hit their FDA primary endpoint at the 50 mg dose. Pooled placebo-adjusted Week-8 remission was +16.4% (p<0.0001), with ABTECT-1 at +19.3% and ABTECT-2 at +13.4% — run across 1,275 patients in 36 countries.

Phase 3 ABTECT Maintenance Results — The Big One (June 1, 2026) ≈50–51% Week-44 clinical remission vs ≈10.4% placebo, with ≈40% placebo-adjusted benefit at both doses. GlobeNewswire's press release called it "landmark." It was. But then came the problem.

The Malignancy Signal — Why the Stock Crashed ≈43% (June 2, 2026) Alongside the efficacy win, a handful of prostate, breast, and skin cancer cases appeared at the 50 mg dose. Abivax said the events were deemed unrelated to treatment and not clustered around a specific organ, and still guided a Q4 2026 NDA filing. The market didn't care about the nuance — the stock fell to $72.50 intraday, wiping out billions in market cap before partially recovering.

Leerink's Thomas Smith noted that AbbVie's Rinvoq carries a malignancy warning and does $8.3B/yr in revenue — a fair analog suggesting the signal is not necessarily disqualifying. But it is a real cloud.

Eli Lilly Takeover Speculation (January 2026) At JPMorgan Healthcare in January 2026, Eli Lilly was reported to be weighing a ≈€15B ($17.5B) takeover of Abivax, with Lilly reportedly seeking guidance from the French Finance Ministry on foreign-investment-control review. Both companies declined to comment. The post-crash drop may have made Abivax more attractive to strategic buyers — ≈44% of institutional investors named ABVX their top 2026 buyout pick.

Cash Runway Secured (Q1 2026) €491.6M cash as of March 31, 2026, with runway into Q4 2027. A ≈$45M ADS offering and royalty-certificate repurchase reduced the royalty overhang without threatening the runway. No forced raise immediately ahead of the December catalysts.

---

Upcoming Catalysts — What the Dec $100 Call Owns

Full ABTECT Safety Dataset / Detailed Maintenance Data — 2H 2026 🔴🔴 High Magnitude, Two-Sided This is the swing event. The complete maintenance safety data package — spelling out exactly how many malignancy cases, at which doses, over what time periods, and whether any pattern is dose-dependent — is expected at a 2H 2026 UC/IBD medical congress. If the full dataset shows the cancer cases were background-rate incidental findings (as Abivax asserts), the overhang lifts materially and the NDA filing gains credibility. If it shows a dose-dependent pattern, all bets are off. This is genuinely the most important event before December.

U.S. NDA Filing — Late Q4 2026 🟢 Positive Trigger (if on time) Abivax has guided a late Q4 2026 U.S. NDA submission for obefazimod in UC — right inside the December 18 option window. Filing the NDA signals that Abivax and its regulatory counsel believe the efficacy + safety package is sufficient for review. An NDA acceptance announcement would be a meaningful positive catalyst even before FDA approval (which is targeted for ≈Q3 2027, outside the option window).

EMA Filing — 2H 2026 The European Medicines Agency pathway runs in parallel. Less U.S.-market-moving but confirms the global regulatory strategy is intact.

ENHANCE-CD (Crohn's Disease) Phase 2b Topline — Q4 2026 or Mid-2027 Guidance has been mixed: the company's earlier guidance pointed to Q4 2026; current pipeline listing suggests mid-2027. If it comes before December, it's pipeline optionality on top of the UC thesis.

M&A / Lilly Takeout — Unscheduled, High Magnitude Stocktwits and institutional surveys suggest Abivax remains a top M&A target — the June crash arguably made the price more actionable for a strategic buyer than it was at $133. A Lilly bid at the reported ≈€15B level would imply a significant premium to current levels. If a deal surfaces before December 18, the Dec $100 call pays out immediately and massively.

ECCO and IBD Congress Presentations — Ongoing 2H 2026 Abivax presented 22 abstracts at ECCO 2026, including first evidence of anti-fibrotic activity. Expect further data presentations at GI-focused congresses through year-end — each a potential incremental positive for the safety narrative.

---

🎲 4-Reader Interpretation

🚀 YOLO Trader

The Dec $100 call structure is already laid out for you. At ≈$28/contract, you're paying a premium that's basically "I think something big happens before December." The trade works if ABVX moves past $128 by expiry (or if you sell the calls earlier when IV spikes on any positive catalyst). You could go further out-of-the-money (say Dec $120 or $130 calls) at lower cost to increase leverage — but the probability drops meaningfully. The desk went right at the money, which tells you something: they're betting on getting in the game, not on a specific price target. Max loss is 100% of what you pay.

📊 Swing Trader

The $100 gamma wall / pin point is your key level. The gamma data shows $100 is the dominant two-sided anchor in the entire ABVX options chain. Here's the playbook: watch for a catalyst (safety data release, NDA filing announcement, or M&A headline) to break the stock cleanly above $100 on volume. Once that gamma pin breaks, the next resistance shelf is $105, and then $110. A pre-catalyst entry on dips toward $95–$97 (where the next put-gamma support sits) gives you better pricing than chasing at $100. The 35-day implied move already reaches $132 by July 17 OPEX — if a catalyst hits before then, the upside move could exceed that.

🛡️ Premium Collector

This name is high-risk for premium selling. The $100 pin makes it tempting to sell straddles or strangles around current price, but a binary safety-data or M&A headline can gap the stock 30–40% in hours — as it just did on June 2. If you must sell premium: very small size, wide strikes, near-term only (weekly), and be prepared to close immediately on any catalyst news. The ±11.65% weekly implied move means the options are already pricing in significant movement even at 6-day expiry. This is not a theta-farm name — it's a gamma-event name.

🌱 Entry-Level / Beginner

Here's what happened in plain English: someone paid ≈$2.1M for the right to buy Abivax stock at $100 per share anytime before December 18, 2026. They paid $28 per contract — which sounds expensive, and it is. But Abivax is a company whose stock can move 40% in a single day (it just did), so options on it are priced to reflect that risk. The buyer is betting that before December, either the company files its drug application with the FDA (a positive regulatory milestone), the safety concerns from June get resolved with clean data, or Eli Lilly completes a takeover. If any of those things happen and the stock climbs above $128, this call makes money. If ABVX stays below $100 on December 18, the call expires worthless and the buyer loses the full $2.1M. This is a high-risk, defined-loss bet on a binary biotech event — not a conservative play.

---

⚠️ Risk Factors

Options trading involves substantial risk of loss and is not suitable for all investors. The specific risks for this trade are unusually elevated:

The Malignancy Signal Is Not Resolved (Primary Risk) The June 2026 crash happened for a reason. Prostate, breast, and skin cancers appearing at the 50 mg dose — even if Abivax says they're unrelated — could force a boxed warning on the label, restrict approval to 25 mg only, or trigger an FDA Advisory Committee (AdCom) review. An AdCom is a major uncertainty event. The full safety dataset due 2H 2026 is genuinely two-sided: it either clears the cloud or deepens it.

Binary, Single-Asset Company Nearly 100% of Abivax's value is one drug. There is no revenue, no approved product, and no pipeline fallback if obefazimod fails or gets restricted. If the NDA gets rejected, delayed, or heavily conditioned, the stock could revisit the $70s or lower. This is not a diversified pharma or biotech platform.

NDA Timing Risk — The Option's Central Assumption The entire thesis for the Dec $100 call rests on the late Q4 2026 NDA filing guidance. If Abivax needs more time to compile the safety package — especially given the malignancy signal adding complexity to the submission — the NDA could slip into 2027, past the December 18 expiry. If that happens, the call captures no NDA catalyst.

Option Pricing Is Extreme — Breakeven Requires ≈28% Upside Paying $28 on a $100 stock means the stock needs to reach $128 at expiration just to break even. The June monthly implied move puts $132 at the upper cone — reachable, but not automatic. The option has very high time value baked in; if the stock stays pinned at $100 and catalysts push out into 2027, the call bleeds value significantly even if the stock doesn't fall.

ADR-Specific Risks ABVX trades as an American Depositary Receipt for a French company. Currency fluctuation (EUR/USD), foreign-investment-control rules (which may affect the Lilly deal timeline), and French regulatory dynamics add layers of complexity absent from domestic biotechs.

M&A Is Not a Plan — It's a Hope Both Eli Lilly and Abivax declined to comment on the takeover reports. No deal has been confirmed. Rumors don't pay option premiums.

What the Tape CANNOT Tell Us: We know the mechanism (lit auto-execution), size (765 contracts), premium ($28), and direction (BUY). We do not know the buyer's identity, whether this is standalone or part of a larger hedged structure, their cost basis on any existing equity position, or their stop-loss level. A big lit call buy is a signal of directional interest — it is not a promise of outcome.

---

🎯 The Bottom Line

Here's the deal: someone just paid ≈$2.1M for a December call on a biotech that dropped 43% in a day two weeks ago — and they bought it right at the money, at the exact strike that maps to the company's own NDA filing timeline.

That's not reckless speculation (well, not entirely). It's a structured bet that the binary event calendar — full safety data, NDA filing, possible Lilly deal — delivers a positive resolution before December 18. The $28/contract price reflects the real probability that it doesn't; someone priced that risk and this buyer accepted it anyway.

Analyst consensus sits at ≈$136–$149 average price target — with Citizens at $187, BTIG at $150, Morgan Stanley at $132. Every one of those targets sits above the $128 breakeven. The $90 low-end target from Wedbush is the bear scenario that expires this call worthless.

What to watch:

• 📅 Tomorrow ≈06:30 ET: OPRA OI snapshot — confirm the Dec $100C position opened (expected OI ≈1,151 from today's 386)
• 📅 2H 2026 (timing unspecified): Full ABTECT maintenance safety dataset at a UC congress — the single most important swing event for the entire thesis
• 📅 Late Q4 2026: U.S. NDA filing announcement — the positive trigger the Dec call is positioned for
• 📅 Ongoing: Any Eli Lilly / M&A developments — unscheduled, high magnitude
• 📅 December 18, 2026: ABVX Dec $100C expiration

If you own ABVX stock: The $100 gamma pin is your near-term anchor. Protect yourself — the stock moved 40% in a day before and it can do it again. Consider covered calls above the gamma resistance ($105–$110) to reduce cost basis while the safety story plays out.

If you're watching from the sidelines: The Dec $100 cone stretches to $160.68 on the upside and $34.74 on the downside. That's not a typo — that's a clean picture of the binary biotech risk. Wait for the safety dataset before committing meaningful size. Buying into a catalyst you don't understand the outcome of is how people blow up.

If you're bearish: The malignancy signal is the bear's best friend. An AdCom outcome, a dose-restricted label, or a delayed NDA (past the December 18 option window) are all live scenarios. The $95 gamma support is your first downside target; a break below $90 support opens the door back toward the June lows around $70–$72.

A ≈$2.1M ATM call on a binary biotech with best-in-class efficacy data and a live safety overhang — sized by someone who knows the odds and bought them anyway. Clean thesis, extreme risk, and a very precise calendar. The December 18 expiry was not chosen randomly.

---

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. This analysis is for educational and informational purposes only and does not constitute financial advice or a solicitation to buy or sell securities. The ABVX December 18, 2026 $100 call requires ≈28% upside from the current strike to reach breakeven at expiration ($128), and can expire completely worthless — resulting in 100% loss of premium paid. ABVX is a clinical-stage biotech ADR; all value depends on a single drug asset and binary regulatory outcomes that are inherently unpredictable. Past unusual options activity does not predict future returns. Always conduct your own due diligence and consider consulting a licensed financial advisor before making any trading decisions. Open/close classification is based on size-vs-prior-OI inference and will be confirmed by next-day OPRA open interest data (≈06:30 ET).

Last updated: June 12, 2026

Last updated: 2026-06-15 — next-day OPRA OI resolved the open/close flag (OPEN confirmed).